Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CNR2 | P34972 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16120102 | 0.94 | HPGD (0.53) | HPGDMAPTKDM4ELMNAHTT | |
| SCHEMBL15848966 | 0.87 | HPGD (0.67) | HPGDMAPTKDM4ELMNAHTT | |
| SCHEMBL17461839 | 0.87 | HPGD (0.53) | HPGDMAPTKDM4ELMNAHTT | |
| SCHEMBL16099050 | 0.82 | HPGD (0.76) | HPGDMAPTKDM4ELMNAHTT | |
| SCHEMBL17461828 | 0.81 | HPGD (0.50) | HPGDMAPTKDM4ELMNAHTT | |
| SCHEMBL2774463 | 0.81 | HPGD (0.79) | HPGDMAPTKDM4ELMNAHTT | |
| SCHEMBL16098831 | 0.81 | NPC1 (0.67) | HPGDMAPTKDM4ELMNAHTT | |
| SCHEMBL16093751 | 0.81 | HPGD (0.58) | HPGDMAPTKDM4ELMNAHTT | |
| SCHEMBL16120103 | 0.80 | HPGD (0.57) | HPGDMAPTKDM4ELMNAHTT | |
| SCHEMBL16120094 | 0.80 | HPGD (0.57) | HPGDMAPTKDM4ELMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160024083-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | HEALTH RESEARCH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024083-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | HEALTH RESEARCH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024083-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | HEALTH RESEARCH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2014153043-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | HEALTH RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014153043-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | HEALTH RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024083-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | AR, KLK3, BRDT | HPGD 166/4885MAPT 3324/4885KDM4E 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.